<DOC>
	<DOCNO>NCT00623519</DOCNO>
	<brief_summary>To investigate global incidence endometrial change postmenopausal woman receive Anastrozole adjuvant treatment hormone receptor positive breast cancer .</brief_summary>
	<brief_title>Assessment Endometrial Changes Postmenopausal Women With Breast Cancer Adjuvant Treatment With Anastrozole</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Anastrozole</mesh_term>
	<criteria>Provision Informed Consent Resectable breast cancer patient , histological confirmation Patients eligible receive hormonal adjuvant treatment Anastrozole They allow patient treat adjuvant chemo radiotherapy concurrently Patients previously treat Tamoxifen withdraw treatment due reason endometrial change allow Postmenopausal patient ( age 50 year over/ without menses last months/ FSH level &gt; 40UI/L / woman 50 year FSH level &gt; 40UI/L ) . Women show progesterone and/or estrogen receptor positive . Patients evidence metastatic disease Patients unsuitable receive medication accord Anastrozole label Patients give Informed Consent</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2009</verification_date>
	<keyword>Adjuvant postmenopausal breast cancer woman</keyword>
</DOC>